

# Diane R Mould

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6658086/publications.pdf>

Version: 2024-02-01

28  
papers

1,655  
citations

489802

18  
h-index

563245

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2059  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1375-1385.	0.9	34
2	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 3316.	1.0	6
3	Multi-Criteria Decision Analysis Model for Assessing the Risk from Multi-Ingredient Dietary Supplements (MIDS). <i>Journal of Dietary Supplements</i> , 2021, 18, 293-315.	1.4	11
4	Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approachâ€”an Indian experience. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 55-62.	0.8	13
5	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	0.6	61
6	Approaches to handling missing or â€œproblematicâ€ pharmacology data: Pharmacokinetics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 291-308.	1.3	18
7	Population Pharmacokinetics and Exposureâ€”Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	3
8	Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 224-233.	1.0	8
9	Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 662-669.	0.6	56
10	Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 790-802.	1.0	37
11	Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 35-51.	1.1	13
12	Individualized Dosing of Therapeutic Monoclonal Antibodiesâ€”a Changing Treatment Paradigm?. <i>AAPS Journal</i> , 2018, 20, 99.	2.2	29
13	Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming. <i>AAPS Journal</i> , 2018, 20, 76.	2.2	17
14	A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 650-660.	0.9	116
15	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. <i>AAPS Journal</i> , 2017, 19, 1136-1147.	2.2	26
16	Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohnâ€™s Disease. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1513-1523.	1.6	30
17	Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S116-S128.	1.0	9
18	Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. <i>AAPS Journal</i> , 2017, 19, 215-222.	2.2	62

#	ARTICLE	IF	CITATIONS
19	Drug Development of Therapeutic Monoclonal Antibodies. <i>BioDrugs</i> , 2016, 30, 275-293.	2.2	68
20	The Pharmacokinetics of Biologics: A Primer. <i>Digestive Diseases</i> , 2015, 33, 61-69.	0.8	48
21	Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S51-9.	1.0	44
22	Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 336-347.	1.0	27
23	Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2247-2259.	0.9	232
24	Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. <i>Malaria Journal</i> , 2014, 13, 36.	0.8	29
25	Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside. <i>AAPS Journal</i> , 2014, 16, 925-937.	2.2	41
26	Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 635-646.	2.3	432
27	Population Pharmacokinetic-Pharmacodynamic Modeling of Biological Agents: When Modeling Meets Reality. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 91S-100S.	1.0	12
28	Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. <i>BioDrugs</i> , 2010, 24, 23-39.	2.2	173